Technical Intelligence & Insights
Explore our curated collection of technical analyses and commercial scale-up strategies specifically focused on Asymmetric Hydrogenation. These insights are designed to support R&D and procurement teams in optimizing their supply chains.
Patent CN108147973B details a novel thiourea-catalyzed route for ECPPA, offering superior stereoselectivity and simplified processing for ACE inhibitor manufacturing.
Novel iridium-catalyzed one-pot synthesis offers high enantioselectivity and scalable flow chemistry for pharmaceutical intermediate manufacturing and supply chain optimization.
Patent CN101023092A discloses stable chiral ligands enabling efficient asymmetric hydrogenation. Enhances supply chain reliability and reduces manufacturing costs for global buyers.
Patent CN112209965A details a high-yield rhodium-catalyzed asymmetric hydrogenation route for chiral beta-aminophosphine precursors, offering significant supply chain and cost advantages.
Patent CN110872260B details a Pd-catalyzed asymmetric hydrogenation route for chiral lactams, offering high ee and yield for pharmaceutical intermediates.
Novel patent CN115677771A offers efficient fosfomycin intermediate production with reduced costs and high purity for reliable pharmaceutical supply chains.
Patent CN114085219A details a high-ee synthesis of (1S,6R)-8-benzyl-7,9-dioxo-2,8-diazabicyclo[4.3.0]nonane. This route offers superior yield and purity for reliable pharmaceutical intermediate supply chains.
Novel Ru-BINAP method for L-Phenylephrine HCl reduces costs and improves purity for pharmaceutical supply chains.
Patent CN112645854B details a novel purification method for Apremilast intermediates using PEG-modified catalysts and specific solvent systems to achieve over 99.5% purity.
Advanced manufacturing of L-Phenylephrine HCl using optimized Rh-catalysis for high purity and cost-effective supply chain solutions.
Novel asymmetric hydrogenation route for Apremilast intermediate offering significant cost reduction and supply reliability for pharmaceutical manufacturing partners seeking high-purity intermediates globally.
Patent CN103214520B reveals ionic liquid supported chiral ligands enabling efficient catalyst recovery and high enantioselectivity for pharmaceutical intermediates manufacturing.
Novel patent CN112830879A details a cost-effective Cinacalcet Hydrochloride synthesis using m-trifluoromethyl benzaldehyde, offering significant supply chain and purity advantages.
Patent CN120004955A reveals stable chiral ligands enabling high ee hydrogenation. Reduces metal usage and simplifies supply chain for complex pharmaceutical intermediate manufacturing.
Patent CN111410604A discloses iridium-phosphine oxazoline catalysis for high-purity chiral intermediates, enabling cost reduction in pharmaceutical manufacturing.
Patent CN1495164A details a Rh-catalyzed route to chiral lactones. Offers high ee and scalable process for MMP inhibitor intermediates.
Patent CN1599743A discloses novel tropp ligands enabling high-efficiency asymmetric hydrogenation. Ideal for pharmaceutical intermediate manufacturing with reduced costs.
Patent CN1182125C details a robust route for (2R,2-alpha-R,3a)-2-[1-(3,5-bis(trifluoromethyl)phenyl)ethoxy]-3-(4-fluorophenyl)-1,4-oxazine, offering superior yield and purity for pharmaceutical supply chains.
Novel patent CN106810485A enables high-purity chiral biphenylpyrrolidone production. Eliminating protecting groups reduces waste and enhances supply chain reliability for global pharmaceutical partners.
Patent CN1568304A reveals a catalytic hydrogenation process for cyclopropylalanine derivatives, ensuring high purity and cost-effective supply chain solutions for global pharmaceutical manufacturers.